miR-422a is modulated by IFN-α treatment.

<p>(A) Expression of miR-422a in PBMC <i>in vivo</i> before, during and after IFN-α/RBV treatment (labeled as “Rx”). Error bars represent SEM. P-value was obtained using a paired t-test and FDR is reported. (B) Effects of IFN-α on the expression of miR-422a in CD4+ T cells <i>in vitro</i>; cells were plated at a million cells per well and treated with either 5 U/ml of IFN-α or media as a negative control. (C) Expression of MLH1 in PBMC <i>in vivo</i> before, during, and after IFN-α/RBV treatment. (D) Expression of TP53 in PBMC <i>in vivo</i> before, during, and after IFN-α/RBV treatment. Error bars represent SEM. P-values were obtained using paired Wilcoxon tests. (E) Correlation between TP53 fold induction and MLH1 fold induction in PBMC <i>in vivo</i> during IFN-α/RBV treatment. P-value was obtained using Spearman’s rank test.